Podcast
Questions and Answers
What is the most important factor responsible for anemia in CKD?
What is the most important factor responsible for anemia in CKD?
- Blood loss during dialysis
- Decreased erythropoietin production (correct)
- Shorter life span of white blood cells
- Iron deficiency
What is the prevalence of anemia among patients with a GFR less than 15 mL/minute?
What is the prevalence of anemia among patients with a GFR less than 15 mL/minute?
- 100%
- 50%
- 26%
- 75% (correct)
When should the evaluation for anemia be initiated in CKD according to the text?
When should the evaluation for anemia be initiated in CKD according to the text?
- When hemoglobin is greater than 15 g/dL
- When hemoglobin is less than 10 g/dL
- When hemoglobin is less than 8 g/dL
- When hemoglobin is less than 13 g/dL (men) or less than 12 g/dL (women) (correct)
Which of the following is a treatment for anemia in CKD as mentioned in the text?
Which of the following is a treatment for anemia in CKD as mentioned in the text?
What is the advantage of Methoxy polyethylene glycolProcrit and epoetin beta over Epoetin alfa?
What is the advantage of Methoxy polyethylene glycolProcrit and epoetin beta over Epoetin alfa?
What is the recommended dosage of erythropoiesis-stimulating agents (ESA) for non-dialysis patients with chronic kidney disease (CKD) when their hemoglobin is greater than 10 g/dL?
What is the recommended dosage of erythropoiesis-stimulating agents (ESA) for non-dialysis patients with chronic kidney disease (CKD) when their hemoglobin is greater than 10 g/dL?
When does the onset of hemoglobin increase occur after the initial dose of Mircera according to the text?
When does the onset of hemoglobin increase occur after the initial dose of Mircera according to the text?
What is the most common cause of erythropoietin resistance in patients receiving ESA therapy for CKD?
What is the most common cause of erythropoietin resistance in patients receiving ESA therapy for CKD?
What is the main cause of morbidity and mortality in patients undergoing dialysis due to chronic kidney disease-mineral and bone disorder (CKD-MBD)?
What is the main cause of morbidity and mortality in patients undergoing dialysis due to chronic kidney disease-mineral and bone disorder (CKD-MBD)?
What are the consequences of CKD-MBD?
What are the consequences of CKD-MBD?
What is a recommended nondrug therapy for CKD-MBD?
What is a recommended nondrug therapy for CKD-MBD?
What is the therapy goal for erythropoiesis-stimulating agents in patients with CKD?
What is the therapy goal for erythropoiesis-stimulating agents in patients with CKD?
What is the recommended cumulative or total dose of iron for adult patients undergoing dialysis?
What is the recommended cumulative or total dose of iron for adult patients undergoing dialysis?
Which factor directly stimulates parathyroid hormone (PTH) secretion and elevates PTH concentrations in CKD-MBD?
Which factor directly stimulates parathyroid hormone (PTH) secretion and elevates PTH concentrations in CKD-MBD?
What should be monitored during erythropoietic therapy in patients with CKD?
What should be monitored during erythropoietic therapy in patients with CKD?
